Alzheimer’s danger may start on the boundaries of the brain, not inside

A new study of Gladstone and UC San Francisco (UCSF) institutes revealed that many genetic risk factors for neurological diseases such as Alzheimer’s and stroke exercise their effects within these guardian cells.

“When studying diseases that affect the brain, most research focused on resident neurons.” “I hope that the results we have reached will lead to more attention to cells that make up the boundaries of the brain, which may actually get the center of the lead in diseases such as Alzheimer’s.”

The results published in Nerve cellsTreating a long -term question about the place where genetic risks begin and indicate that the weaknesses of the defense system in the brain may serve as a major operator of the disease.

The fee for the maps of the guardians on the brain

Over the years, genetic studies have been widely linked to dozens of DNA variables with higher risks of neurological diseases such as Alzheimer’s, Parkinson’s or Multiple Sclerosis.

However, the main ambiguity continued: no more than 90 % of these variables in the genes themselves, but in the surrounding DNA that does not contain the code to make proteins, as soon as it rejects it “unwanted DNA”. These areas act as complex, complex keys, operating or stopping genes.

Until now, scientists have no full map that controls genes or specific brain cells that operate, hindering the path of genetic discovery to new treatments.

New technology find answers

The blood barrier in the brain is the defense of the anterior line of the brain-a cellular boundaries consisting of vascular cells, immune cells, and other supportive cells that accurately control access to the brain.

However, it was difficult to study these important cells, even using the most powerful genetic techniques in the field. To overcome this, the Gladstone Multivine -seq team, a technique that gently isolated vascular and immune cells from the human brain tissue after death.

This technology allowed the team, for the first time, to plan two layers of information simultaneously: genetic activity and “low switching” settings – known as access to chromatin – within each cell. Scientists have studied 30 samples of the brain from individuals who suffer from a neurological disease, which gives them a detailed look at how genetic variables of genetic risks work in all types of main brain cells.

Work closely with Gladstone Ryan Corcels, PhD, Katie Pollard, PhD, MADIGAN ReID, PHDs, and Shreya Menon incorporating the atlas of one cell with wide genetic data from Alzheimer’s studies, stroke, and other brain diseases. This revealed the place where the variables associated with diseases are active-and many of them have been active in vascular and immune cells instead of neurons.

“Before that, we knew that these genetic variables increase the risk of disease, but we did not know where or how they acted in the context of the types of brain barrier cells.” “Our study shows that many variables are already operating in the blood vessels and immune cells in the brain.”

Various diseases, various disorders

One of the most exciting results is that the genetic variables of genetic risks affect the system of the brain barrier mainly in various ways, depending on the disease.

“We were surprised by a vision that the genetic drivers of stroke and Alzheimer’s have had such distinctive effects, although both of them involved blood vessels in the brain,” says Reed. “This tells us that it contains really distinctive mechanisms: structural weakness in stroke, and functionally disturbed immunity signals in Alzheimer’s disease.”

In stroke, genetic variables primarily affect the genes responsible for the structural safety of the blood vessels, which may weaken the physical structure of the vessels. While in Alzheimer’s disease, genes that regulate immune activity, indicating that excessive activity inflammation – not structural weakness – is the main issue.

Between Alzheimer’s variables, one stood up. Common alternative near Ptk2b The gene, found in more than a third of the population, was more active in T -cells, a type of immune cell. The alternative enhances the expression of the gene, which may enhance the activation of T cells and entry into the brain, putting the immune cells in increased speed. The team found these immune cells with superior charging near the amyloid plaques, which is the accumulation of sticky protein that determines Alzheimer’s disease.

“Scientists discuss the role of T cells and related components of the immune system in Alzheimer’s disease,” says Yang. “Here, we offer genetic evidence in humans that the risk of joint Alzheimer’s disease may work through T cells.”

With excitement, Ptk2b It is a well -known “drug” goal, and the treatments that prevent its function are already present in the clinical trials of cancer. The new study opens a new way to investigate whether these drugs can be reused for Alzheimer’s disease.

The site, the site, the site

The results of the study on the “guardian” cells of the brain indicate two new opportunities to protect the brain.

The cells are located in the critical interface between the brain and the body, and the cells are constantly affected by the lifestyle and environmental exposure, which can erode with the genetic preparations to push the disease. Their site also makes a promising target for future treatments, which may allow drugs that can enhance brain defenses from “outside” without the need to cross the blood barrier in the huge brain.

“This work brings vascular and immune cells to the brain to the spotlight,” says Yang. “Given their unique position and their role in establishing the brain relationship with the body and the outside world, our work can reach new targets for medicines and new lifestyle interventions to protect the brain from the outside.”

About study

The study was published, “Human Brain Vascular Multi-Laomics, showing the connections of the risk of pathogens”, in the magazine Nerve cells On July 28, 2025.

In addition to Yang, Red, Corpus, and Burolard, the other authors are Shris Menon, Haw Liu, Hawwo Chu, Chiroi is, Bella Deng, Zimo Zhang, Sophia Nelson, and Imana Apollonio from Glaston; Simon Freich from the University of California, San Francisco; Sharam Offesgaran and David A. Bennett from the Medical Center of Rush University; And Martin Dietagens from LMU Munich.

This work was supported by the National Institute for Neurological Disorders and Stroke (1R01NS128909-01), Alzheimer’s Society (ADSF-24-1345199-C, Aarf-22-923641), Brightfocus (A2022027F), Alzheimer’s Foundation, The Dolby Family. Research Institute, National Institute of Mental Health (R01-503 MH123178), National Institute of Agency (P01-Ag073082, U01-Ag072573), LEDUCQ (22CVD01, Brenda), Joachim Herz, and National Genome Research Foundation (UM1-HG012076).